{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Liu KJ"],"funding":["National Health Research Institutes"],"pubmed_abstract":["Background
To better evaluate and improve the efficacy of dendritic cell (DC)-based cancer immunotherapy, we conducted a clinical study of patients with advanced colorectal cancer using carcinoembryonic antigen (CEA)-pulsed DCs mixed with tetanus toxoid and subsequent interleukin-2 treatment. The tetanus toxoid in the vaccine preparation serves as an adjuvant and provides a non-tumor specific immune response to enhance vaccine efficacy. The aims of this study were to (1) evaluate the toxicity of this treatment, (2) observe the clinical responses of vaccinated patients, and (3) investigate the immune responses of patients against CEA before and after treatment.Methods
Twelve patients were recruited and treated in this phase I clinical study. These patients all had metastatic"],"journal":["Journal of biomedical science"],"pagination":["64"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4997699"],"repository":["biostudies-literature"],"pubmed_title":["A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment."],"pmcid":["PMC4997699"],"pubmed_authors":["Chang JY","Chao TY","Yu WL","Ch'ang HJ","Wu YC","Whang-Peng J","Liu KJ","Kao WY","Chung TR","Cheng AL"],"additional_accession":[]},"is_claimable":false,"name":"A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.","description":"Background
To better evaluate and improve the efficacy of dendritic cell (DC)-based cancer immunotherapy, we conducted a clinical study of patients with advanced colorectal cancer using carcinoembryonic antigen (CEA)-pulsed DCs mixed with tetanus toxoid and subsequent interleukin-2 treatment. The tetanus toxoid in the vaccine preparation serves as an adjuvant and provides a non-tumor specific immune response to enhance vaccine efficacy. The aims of this study were to (1) evaluate the toxicity of this treatment, (2) observe the clinical responses of vaccinated patients, and (3) investigate the immune responses of patients against CEA before and after treatment.Methods
Twelve patients were recruited and treated in this phase I clinical study. These patients all had metastatic","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Aug","modification":"2026-06-16T05:02:12.742Z","creation":"2019-03-27T02:22:37Z"},"accession":"S-EPMC4997699","cross_references":{"pubmed":["27558635"],"doi":["10.1186/s12929-016-0279-7"]}}